[Efficacy and safety of vaccination against yellow fever of persons traveling to endemic areas].
OBJECTIVE
To asses the yellow fever effectiveness in persons traveling to the endemic regions, and the frequency of adverse events related to vaccine as well as the change of neutralizing antibodies in time.


METHODS
Fifty three persons (25 males and 28 females, mean 43.5 years) vaccinated against yellow fever in 2004-2008 were involved to the study. In 2009 the level of serum anti-yellow fever antibodies was measured by neutralization test. MAIN OBSERVATION AND RESULTS: None of studied person demonstrated adverse events related to yellow fever vaccine. Four subjects (7.5%) did not respond appropriately to the vaccine. There was no correlation between the level of neutralizing antibodies and gender, age, co-morbidities presence and duration of time after vaccination.


CONCLUSIONS
Currently used anti-yellow fever vaccine demonstrates high level of efficacy and safety. Above 92% of studied persons had protective level of neutralizing antibodies. Moreover, the postvaccinal response seems to be long-term and does not depend on time period from vaccination or other factors.
Dabrowska
Magdalena M
MM
Klinika Chorób Zakaźnych i Hepatologii Uniwersytetu Medycznego w Białymstoku.
Flisiak
Robert
R
D000222:Adaptation, Physiological / Q000276:immunology; D000328:Adult; D000349:Africa; D002489:Central America; D019353:Endemic Diseases / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D008875:Middle Aged; D011044:Poland; D014195:Travel; D015004:Yellow Fever / Q000453:epidemiology* / Q000517:prevention & control*; D022341:Yellow Fever Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D055815:Young Adult
D022341:Yellow Fever Vaccine